Randomized trial assesses the socioeconomic gradient of varicella burden, revealing crucial implications for health strategies.
Background: Varicella burden is closely linked to national socioeconomic development, yet systematic analyses of its non-linear relationship with the Socio-demographic Index (SDI) are lacking. This study aims to elucidate this relationship and inform equitable, context-specific strategies. Methods: Based on data from the Global Burden of Diseases 2021 study, we analyzed global trends (1990–2021) in the incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of varicella. Joinpoint regression was used to identify trend transition points, and an autoregressive integrated moving average (ARIMA) model was applied to forecast the disease burden through 2035. Analyses were conducted, and countries and territories were stratified into five SDI groups: high (SDI > 0.81), high–middle (0.70–0.81), middle (0.61–0.69), low–middle (0.46–0.60), and low (SDI < 0.46). These approaches aimed to systematically elucidate the socioeconomic gradient of the varicella burden and to specifically investigate its potential non-linear relationship with SDI. Results: From 1990 to 2021, global age-standardized mortality and DALYs declined by −45.71% (95% UI: −48.32% to −42.95%) and −36.15% (95% UI: −39.04% to −33.01%), respectively, while incidence and prevalence rates slightly increased. A significant U-shaped relationship emerged between burden and SDI, with rates highest in low- and high-SDI regions. The rise in high-SDI regions was driven by increasing incidence and prevalence from 1996 to 2015. Projections to 2035 indicate continued global decline but persistent disparities. Conclusions: The varicella burden follows a U-shaped socioeconomic gradient. Rising incidence in high-SDI regions highlights that economic development and routine pediatric vaccination alone are insufficient. Precision strategies tailored to SDI levels—closing adult immunity gaps in high-SDI, sustaining gains in middle-SDI, and expanding vaccine access in low-SDI regions—are essential.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: